Clinical Assistant Professor, Pathology, University Hospitals Cleveland Medical Center  

Associate Director, Oncology Product Management, Thermo Fisher Scientific 

This webinar will discuss how next-generation sequencing (NGS) can help clinical research labs and pathologists save time, money, and samples compared to single-analyte oncology research assays.

Recent studies estimate that almost 73 percent of cancer treatments in the pipeline may need a genomic biomarker in the next few years. As the list of genomic biomarkers relevant to clinical oncology keeps growing, the ability to detect mutations across hundreds of targets in a rapid, cost-efficient fashion helps pathology research laboratories conserve samples by reducing the need for sequential, single-analyte assays. NGS panels have revolutionized the field of cancer genomics by enabling pathologists and clinical researchers to analyze mutations across multiple genes, in a single assay.

For clinical research or pathology laboratories that are considering adopting NGS in house, it’s important that the chosen solutions are compatible with challenging sample types (such as fine needle aspirates and formalin-fixed, paraffin-embedded samples), have an automated wet-lab workflow, and offer plug-and-play bioinformatics capabilities.

In this webinar, Dr. Navid Sadri of the University Hospitals Cleveland Medical Center will provide an overview of why his pathology lab adopted NGS and how it is being implemented for clinical research. He will provide some examples of how NGS helped identify different mutation types and provided relevant results with limited sample input and a rapid turnaround time.

Thereafter, Dr. Jody McIntyre of Thermo Fisher Scientific will show how Oncomine KnowledgeBase Reporter can help pathologists and clinical researchers link cancer variants to labels, guidelines and clinical trials, and generate an easy-to-interpret report in a few simple steps.

Medical Director, Molecular Oncology Diagnostics Lab
The Ottawa Hospital

This webinar will demonstrate a new approach that combines precise FFPE tumor isolation with extraction-free DNA/RNA library preparation to minimize material losses and reduce the amount of tissue input required for NGS analysis.

The need to process small quantities of solid tumor specimens is increasing as early detection strategies become more effective and less invasive biopsy strategies are adopted. Moreover, the rapidly changing landscape of molecular testing points towards a need for minimizing sample input and preservation of sample for future testing. Processing small areas of dissected tumor can be challenging as traditional manual macrodissection and purification methods include multiple steps during which material can be lost.

In this webinar, Bryan Lo, Medical Director of the Molecular Oncology Diagnostics Lab at the Ottawa Hospital, will present a new approach that combines automated tissue dissection with NGS library prepared directly from fragments of dissected tissue.

Dr. Lo will discuss a study that demonstrated that gene expression profiling of pancreatic cancer and precursor lesions extracted by automated tissue dissection system yielded highly correlated data across tissue samples. Furthermore, mutation screening of dissected tissue fragments from melanoma and colorectal cancer showed high correlation between libraries prepared from an extraction-free method vs extracted DNA.

Taken together, these findings demonstrate that an automated tissue dissection approach joined with extraction-free library preparation can help efficiently process extremely small samples that are otherwise too challenging for standard NGS analysis.

Attendees of this webinar will learn the following:

  • Current challenges with isolating precise tumor areas of interest from FFPE tissue samples
  • How a high-performance, automated tissue dissection system can extract challenging tumor tissue fragments precisely and consistently
  • How to subsequently prepare NGS libraries using extraction-free methods to further reduce the risk of sample loss

Associate Director, Marie-Josée & Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center

Chief Technology Officer, Philips Genomics

This webinar will present an in-depth look at how Memorial Sloan Kettering Cancer Center has developed and implemented a next-generation sequencing panel for mutational tumor profiling of advanced cancer patients.

Michael Berger, Associate Director of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology at Memorial Sloan Kettering Cancer Center, will discuss the implementation of MSK-IMPACT, an NGS panel that analyzes both tumor and matched normal tissue to detect protein-coding mutations, copy number alterations, and certain promoter mutations and structural rearrangements in cancer-associated genes.

The panel, which currently covers 468 genes, has allowed a large number of patients to enroll in clinical trials of targeted treatments, according to a study published by Berger and colleagues earlier this year based on the results from sequencing around 10,000 patients. The MSKCC team found that around a third of these patients harbored actionable mutations and 11 percent of patients participated in a genomically matched clinical trial based on their results.

Since then, the MSKCC team has profiled a total of 20,000 patients with the panel. Dr. Berger will discuss lessons learned from this implementation process, including:

  • Considerations in assay design
  • Challenges in large-scale implementation
  • Integration with informatics systems
  • Assessment of clinical utility
  • Opportunities for clinical, translational, and basic research

Dr. Nevenka Dimitrova will discuss how the Philips IntelliSpace Genomics platform addresses the challenges of implementing molecular profiling panels at healthcare systems with integrated clinical-genomic data, up-to-date variant interpretation and seamless workflow for precision oncology.

Recent GenomeWebinars

Assistant Professor of Medicine, Dana-Farber Cancer Institute, Harvard Medical School

Chief Technology Officer, Philips Genomics 

This webinar provides an overview of how liquid biopsies can be integrated into lung cancer care.

Genotyping of plasma cell-free DNA is rapidly changing the management approach for genotype-defined lung cancers. Widely available assays now have the ability to noninvasively identify driver mutations in cfDNA, monitor response to therapy, and characterize emerging resistance. However, such liquid biopsies also have clear limitations and existing assays are unlikely to replace tumor biopsies completely.

In this webinar, Geoffrey Oxnard of Dana-Farber Cancer Institute discusses an optimal approach for integrating liquid biopsies into lung cancer care, while also providing his outlook on how liquid biopsies may become a routine part of lung cancer treatment in the years ahead. 

Dr. Dimitrova discusses how the Philips IntelliSpace Genomics platform brings data from liquid biopsies (and other NGS tests) alongside disease histology and patient phenotype for a complete clinical picture for clinical decision making.

11:00 am2017
Sponsored by

Case Study: Development and Validation of Clinical ctDNA Cancer Assays


 Associate Chair, Surgical Research and Associate Professor of Surgery, Boston University School of Medicine 

This webinar is the last in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.

If you are a clinical laboratory that is currently running or about to begin offering NGS-based clinical genomics testing and want to know how other labs have addressed specific validation and daily implementation challenges, this webinar series is for you!

Labs looking to implement NGS diagnostics face a number of regulatory challenges. These tests currently fall under the Clinical Laboratory Improvement Amendment guidelines as laboratory developed tests and lack specific validation guidelines and global performance standards. Moreover, these assays feature complex workflows comprised of hardware, wetware, and software from multiple vendors assembled — far different from more standardized approaches that fall under the Food and Drug Administration's guidelines for in vitro diagnostics.

During this webinar, Tony Godfrey of the Boston University School of Medicine discusses how his lab is developing and validating clinical circulating tumor DNA assays. 

Sponsored by

CEO, Director & Co-Founder,
Clinical Genomics

Associate Director, New Product Quality Assurance,

This online seminar provides an overview of the use of liquid biopsies for cancer recurrence monitoring with a particular focus on colorectal cancer.

Analysis of circulating tumor DNA (ctDNA) has the potential to improve detection and monitoring of cancers in order to significantly impact patient outcomes. This is especially important for cancers with a high rate of recurrence, such as colorectal cancer, where between 30 percent and 40 percent of cases recur. However, the only currently available monitoring blood test misses 74 percent of resectable recurrences.

In this webinar, Dr. Lawrence LaPointe, CEO of Clinical Genomics, discusses how his team is working with Qiagen to develop a ctDNA test for colorectal cancer recurrence monitoring.

Additionally, Dr. Martin Horlitz briefly shares how Qiagen's ctDNA extraction chemistries are compliant with ISO and IVD quality guidelines.

Sponsored by